Synergic Medical Technologies
Eugene, Oregon, 97403, United States
NCT Number: NCT05830110
The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses a novel stimulation pattern to disrupt the pathophysiological mechanism that is responsible for PD symptoms and thus restore motor function.
This study is active but is not currently recruiting participants.
Notify Me45 year–90 year
All sexes
Interventional
Not applicable
Eugene, Oregon, 97403, United States
Up to thirty adults with bilateral, moderate stage idiopathic PD will be enrolled in this longitudinal study. Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals. This longitudinal protocol will be open-ended to enable continued treatment to those interested / motivated.
Study treatment will consist of daily, four-hour vibrotactile Coordinated Reset (vCR) stimulation sessions on a continual basis. All daily vCR stimulation sessions will occur at the participant's home (ON-medication) and can be broken up into two, two-hour blocks (with no more than 12 hours between stimulation blocks) to be less cumbersome and better integrate into the participant's daily life. Daily home-based treatment will be unsupervised, though timely support is guaranteed by Synergic Medical Technologies (SMT) support staff when needed (e.g., when usability or IT issues arise). Daily stimulation / device usage will be automatically logged by the device and continuously monitored by SMT staff, meanwhile participants will keep a med diary so we can monitor their med usage (and how it relates to extended exposure) over time. Participants will be able to transition to an as-needed basis with treatment after four months and once they are familiar with the treatment and their body's response to it, to better alleviate PD symptoms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Gloves providing vibrotactile coordinated reset stimulation
Gloves providing sham vibrotactile coordinated reset stimulation
Time frame: baseline, 2 months, 4 months
Change in MDS-UPDRS score using Part 3 of the scale.
Synergic Medical Technologies, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05410392
Basal Ganglia Diseases, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07678983
Balance, Basal Ganglia Diseases
Izmir, Turkey (Türkiye)
View Trial DetailsNCT03100149
Basal Ganglia Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT02994719
Ataxia, Ataxia, Spinocerebellar
Boston, Massachusetts, United States
View Trial Details